ライフサイエンスコーパス: antipsychotic agent

1 evelopment of 2 as a novel second-generation antipsychotic agent.

2 variant was applied to rodents receiving an antipsychotic agent.

3 uperior therapeutic effects of this atypical antipsychotic agent.

4 several of the criteria for a novel atypical antipsychotic agent.

5 se I clinical trials as a potential atypical antipsychotic agent.

6 estigated as an approach to a novel atypical antipsychotic agent.

7 mplications for understanding the actions of antipsychotic agents.

8 st-generation and several recently-developed antipsychotic agents.

9 , indicating their potential as nonclassical antipsychotic agents.

10 rom monitoring should guide the selection of antipsychotic agents.

11 ffect of race on the use of various atypical antipsychotic agents.

12 nd release and may have potential utility as antipsychotic agents.

13 prepared and evaluated as potential atypical antipsychotic agents.

14 occupancy of striatal dopamine receptors by antipsychotic agents.

15 isdiagnosis and inappropriate treatment with antipsychotic agents.

16 1), were prepared and evaluated as potential antipsychotic agents.

17 cy of four novel, evidence-based targets for antipsychotic agents: a neurokinin (NK(3)) antagonist (S

18 tion may be useful for testing potential new antipsychotic agents and for characterizing neurobiologi

19 er between psychiatric subjects treated with antipsychotic agents and normal controls.

20 In light of the efficacy of newer antipsychotic agents and the possibility that drug withd

21 rugs is associated with clinical response to antipsychotic agents and the production of extrapyramida

22 n the biological activity of these potential antipsychotic agents are discussed.

23 (3) receptors targeted by the most effective antipsychotic agents are maximally expressed, could lead

24 stigated the efficacy of lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium

25 hanges in response to the advent of atypical antipsychotic agents can be understood in the context of

26 3, that have been evaluated in the clinic as antipsychotic agents (Chart 2).(2)

27 m chloride or systemic administration of the antipsychotic agent clozapine.

28 Sertindole is a new antipsychotic agent effective for the treatment of both

29 The newer antipsychotic agents exhibit a superior safety profile c

30 Olanzapine is a novel antipsychotic agent exhibiting regional mesolimbic dopam

31 e benefits of the continued use of a typical antipsychotic agent following remission from an acute ma

32 ere 18 to 68 years old, were treated with an antipsychotic agent for 6 months or more at a stable dos

33 panel recommendations regarding choice of an antipsychotic agent for schizophrenia differ markedly, b

34 n criteria were >/=18 years old, were taking antipsychotic agents for >/=30 days, and had a body mass

35 receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D2 ratio co

36 Patterns of clinical use of antipsychotic agents have changed greatly in the past de

37 2.89; 95% CI, 1.51 to 5.55; P=0.001), or an antipsychotic agent (hazard ratio, 3.02; 95% CI, 1.34 to

38 data on the safety and efficacy of atypical antipsychotic agents in children are limited.

39 cacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder.

40 ic drugs, by definition, differ from typical antipsychotic agents in producing significantly fewer ex

41 or safety profile compared with conventional antipsychotic agents in terms of extrapyramidal symptoms

42 ilize omega-3, anticonvulsants, and atypical antipsychotic agents in treating specific DSM-5 BPD trai

43 However, atypical antipsychotic agents, in combination with the nicotine t

44 therapeutic profile of atypical over typical antipsychotic agents include 1) simultaneous antagonism

45 Novel antipsychotic agents introduce new pharmacological avenu

46 This model for identifying potential antipsychotic agents is based on the hypothesis that age

47 schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypica

48 injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment

49 to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conven

50 Ten C57-B mice received an antipsychotic agent or vehicle control.

51 uation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to tha

52 nuous infusion to examine the effects of the antipsychotic agent RWJ-37796, on striatal activity in h

53 modern psychotropic agents, such as atypical antipsychotic agents, selective serotonin reuptake inhib

54 is response is specific to second-generation antipsychotic agents (SGAs), as first-generation medicat

55 At their clinical doses, current antipsychotic agents share the property of both dopamine

56 The study results suggest that novel antipsychotic agents such as olanzapine should be consid

57 ned with an anxiolytic, mood stabilising, or antipsychotic agent), supportive psychotherapy (often co

58 cinations in schizophrenia are alleviated by antipsychotic agents that inhibit D2 dopamine receptors

59 e 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user c

60 To report the use of a second-generation antipsychotic agent to assist weaning from prolonged mec

61 ferences in mortality risks among individual antipsychotic agents used for treating patients with dem

62 EEG abnormality risk among antipsychotic agents varied greatly (clozapine=47.1%, ol

63 on of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine)

64 This potential antipsychotic agent was not developed further due to und

65 A second-generation antipsychotic agent was successfully used to facilitate

66 t and imaging studies in mice suggested that antipsychotic agents were not confounding the primary fi

67 A number of dopamine receptor antagonist/antipsychotic agents were shown to block hKv2.1.

68 Atypical antipsychotic agents, which block postsynaptic dopamine

69 Further work with other antipsychotic agents will be necessary to determine if i

70 Quetiapine is an atypical antipsychotic agent with a complex pharmacology, includi

71 sses activity consistent with an efficacious antipsychotic agent with less tendency to induce extrapy

72 tial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreas

73 ogues (4a,b and 9a, b) to be the most potent antipsychotic agents with large separation between effic

74 Manufacturers of atypical antipsychotic agents without online registries were cont